Platelets, atherosclerosis and the endothelium: new therapeutic targets?

Bibliography

• ROSS R: Atherosclerosis - an inflammatory disease. N Engl. I Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• MASSBERG S, BRAND K, GRUNER S et al.: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. Exp. Med. (2002) 196:887–896.
   PubMed Web of Science ®Google Scholar
• ••Excellent basic science paper on theimportance of platelets in atherosclerosis.
   Google Scholar
• COLEMAN RA, SMITH WL, NARUMIYA S: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharinacol Rev (1994) 46:205–229.
   PubMed Web of Science ®Google Scholar
• FEELISCH M, TE POEL M, ZAMORA Ret al.: Understanding the controversy over the identity of EDRF. Nature (1994) 368:62–65.
   Google Scholar
• BIRK AV, BROEKMAN MJ, GLADEK EM et al.: Role of extracellular ATP metabolism in regulation of platelet reactivity. J. Lab. Clin. Med. (2002) 140:166–175.
   PubMed Web of Science ®Google Scholar
• FITZPATRICK FA, SOBERMAN R: Regulated formation of eicosanoids. Clin. Invest. (2001) 107:1347–1351.
   Google Scholar
• PATRIGNANI P, SCIULLI MG, MANARINI S et al: COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol PharinacoL (1999) 50:661–667.
   PubMed Web of Science ®Google Scholar
• SMITH WL: The eicosanoids and their biochemical mechanisms of action. Biochein. J. (1989) 259:315–324.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA 0, TANAKA I, USUI T et al.: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation (1994) 90:1643–1647.
   Google Scholar
• NERI SERNERI GG, MODESTI PA, FORTINI A et al.: Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet (1984) 2:838–841.
   PubMed Web of Science ®Google Scholar
• FEINSTEIN MB, EGAN JJ, SHA'AFI RI,WHITE J: The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin). Biochein. Biophys. Res. Commun. (1983) 113:598–604.
   PubMed Web of Science ®Google Scholar
• DUSTING GJ, MACDONALD PS: Prostacyclin and vascular function: implications for hypertension and atherosclerosis. Pharmacol Then (1990) 43:323–344.
   Google Scholar
• TAKAHARA K, MURRAY R, FITZGERALD GA, FITZGERALD DJ: The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J. Biol. Chem. (1990) 265:6836–6844.
   Google Scholar
• HALUSHKA PV, MAIS DE, SAUSSY DL Jr: Platelet and vascular smooth muscle thromboxane A2/ prostaglandin H2 receptors. Fed. Proc. (1987) 46:149–153.
   PubMedGoogle Scholar
• SACHINIDIS M, FLESCH Y, KO K et al: Thromboxane A(2) and vascular smooth muscle cell proliferation. Hypertension (1995) 26:771–780.
   PubMed Web of Science ®Google Scholar
• FITZGERALD DJ, ROY L, CATELLA F, FITZGERALD GA: Platelet activation in unstable coronary disease. N EngL Med. (1986) 315:983–989.
   PubMed Web of Science ®Google Scholar
• DAVI G, GRESELE P, VIOLI F et al: Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation (1997) 96:69–75.
   Google Scholar
• KAWASAKI T, OZEKI Y, IGAWA T, KAMBAYASHI J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke (2000) 31:591–595.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, HANKEY GJ: Aspirinresistance: a new independent predictor of vascular events? Am. Coll CardioL (2003) 41:966–968.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• •The definitive guide to aspirin therapy.
   Google Scholar
• GUM PA, KOTTKE-MARCHANT K, WELSH PA et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll Cardiol (2003) 41:961–965.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, HIRSH J, WEITZ JI et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 105:1650–1655.
   PubMed Web of Science ®Google Scholar
• KARIM S, HABIB A, LEVY- TOLEDANO S et al.: Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem. (1996) 271:12042–12048.
   Google Scholar
• MORROW JD, HILL KE, HILL KE et al.: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA (1990) 87:9383–9387.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI K, NAMM OUR TM, FUKUNAGA M et al.: Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J. Clin. Invest. (1992) 90:136–141.
   Google Scholar
• AUDOLY LP, ROCCA B, FABRE JE et al: Cardiovascular responses to the isoprostanes iPF(2a)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation (2000) 101:2833–2840.
   PubMed Web of Science ®Google Scholar
• GRESELE P, DECKMYN H, NENCI GG, VERIVIYLEN J: Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends PharmacoL Sci. (1991) 12:158–163.
   PubMed Web of Science ®Google Scholar
• BALSANO F, VIOLI F: Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation (1993) 87:1563–1569.
   PubMed Web of Science ®Google Scholar
• BUCCELLATI C, CICERI P, BALLERIO R et al.: Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction. Ear: J. Pharmacol (2002) 443:133–141.
   PubMed Web of Science ®Google Scholar
• RATTI S, OUARATO C, CASAGRANDE R et al.: Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. Eur. Phannacol (1998) 355:77–83.
   PubMed Web of Science ®Google Scholar
• COCCOZZA M, PICANO T, OLIVIERO U et al.: Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double blind, placebo-controlled study in diabetic patients. Stroke (1995) 26:597–601.
   Google Scholar
• ••Good paper on the atheromodulatoryeffect of a neglected class of drugs.
   Google Scholar
• CAYATTE AJ, DU Y, OLIVER-KRASINSKI J et al.: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vase. Biol. (2000) 20:1724–1728.
   PubMed Web of Science ®Google Scholar
• GACHET C, CATTANEO M, OHLMANN P et al.: Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br. J. Haematol (1995) 91:434–444.
   PubMed Web of Science ®Google Scholar
• JIN J, DANIEL JL, KUNAPULI SP: Molecular basis for ADP-induced platelet activation. J. Biol. Chem. (1998) 273:2030–2034.
   PubMed Web of Science ®Google Scholar
• OURY C, TOTH-ZSAMBOKI E, THYS C et al.: The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb. Haemost. (2001) 86:1264–1271.
   PubMed Web of Science ®Google Scholar
• HOLLOPETER G, JANTZEN H, VINCENT D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 409:202–207.
   PubMed Web of Science ®Google Scholar
• SAVI P, PEREILLO JM, UZABIAGA MFet al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. (2000) 84:891–896.
   Google Scholar
• BHATT DL, HIRSCH AT, RINGLEB PA et al.: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am. Heart J. (2000) 140:67–73.
   PubMed Web of Science ®Google Scholar
• BAURAND A, GACHET C: The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc. Drug Rev (2003) 21:67–76.
   PubMedGoogle Scholar
• MARCUS AJ, BROEKMAN MJ, DROSOPOULOS JH et al: The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. Clin. Invest. (1997) 99:1351–1360.
   Google Scholar
• ROBSON SC, KACZMAREK E, SIEGEL JB et al.: Loss of ATP diphosphohydrolase activity with endothelial cell activation. J. Exp. Med. (1997) 185:153–163.
   PubMed Web of Science ®Google Scholar
• GANGADHARAN SP, IMAI M, RHYNHART KK et al.: Targeting platelet aggregation: CD39 gene transfer augments nucleoside triphosphate diphosphohydrolase activity in injured rabbit arteries. Surgery(2001) 130:296–303.
   PubMed Web of Science ®Google Scholar
• MARCUS AJ, BROEKMAN MJ, DROSOPOULOS JH et al.: Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital. Heart J. (2001) 2:824–830.
   PubMedGoogle Scholar
• MARCUS AJ, SAFIER LB, HADAR KA et al.: Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. Clin. Invest. (1991) 88:1690–1696.
   PubMed Web of Science ®Google Scholar
• LEDENT C, VAUGEOIS JM, SCHIFFMANN SN et al.: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature (1997) 388:674–678.
   PubMed Web of Science ®Google Scholar
• SALZMAN EW: Cyclic AMP and platelet function. N Engl. J. Med. (1978) 286:358–363.
   Google Scholar
• MELLION BT, IGNARRO LJ, OHLSTEIN EH et al.: Evidence for the inhibitory role of guanosine 3',Y-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood(1981) 57:946–955.
   PubMed Web of Science ®Google Scholar
• MURAD F: Cyclic guanosine monophosphate as a mediator of vasoclilation.j Clin. Invest. (1986) 78:1–5.
   PubMed Web of Science ®Google Scholar
• STASCH JP, BECKER EM, ALONSO-ALIJA C et al.: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410:212–215.
   PubMed Web of Science ®Google Scholar
• WU CC: YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol (1995) 116:1973–1978.
   PubMed Web of Science ®Google Scholar
• HASLAM RJ, DICKINSON NT, JANG EK: Cyclic nucleotides and phosphodiesterases in platelets. Thromb. Haemost. (1999) 82:412–423.
   PubMed Web of Science ®Google Scholar
• FELKER GM, BENZA RL, CHANDLER AB et al.: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. I Am. Coll Cardiol (2003) 41:997–1003.
   PubMed Web of Science ®Google Scholar
• DAWSON DL, CUTLER BS, MEISSNER MH, STRANDNESS DE Jr: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation (1998) 98:678–686.
   PubMed Web of Science ®Google Scholar
• THE PROMISE STUDY RESEARCH GROUP: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• THOMPSON PD, ZIMET R, FORBES WP, ZHANG P: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. Cardiol (2002) 90:1314–1319.
   PubMed Web of Science ®Google Scholar
• IKEDA Y, KIKUCHI M, MURAKAMI H et al.: Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung (1987) 37:563–566.
   PubMed Web of Science ®Google Scholar
• SHINODA-TAGAWA T, YAMASAKI Y, YOSHIDA S et al.: A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia (2002) 45:188–194.
   PubMed Web of Science ®Google Scholar
• TANAKA T, ISHIKAWA T, HAGIWARA M et al: Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology(1998) 36:313–320.
   Google Scholar
• IKEWAKI K, MOCHIZUKI K, NVASAKI M et al.: Cilostazol, a potent phosphodiesterase Type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with Type 2 diabetes mellitus. Metabolism (2002) 51:1348–1354.
   PubMed Web of Science ®Google Scholar
• SANCHEZ LS, DE LA MONTE SM, FILIPPOV G et al.: Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pedian: Res. (1998) 43:163–168.
   Google Scholar
• MICHELAKIS E, TYMCHAK W, LIEN D et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105:2398–2403.
   PubMed Web of Science ®Google Scholar
• SASTRY BK, NARASIMHAN C, REDDY NK et al.: A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart (2002) 54:410–414.
   PubMedGoogle Scholar
• PALMER RIVI, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1998) 333:664–666.
   Google Scholar
• HUANG PL, HUANG Z, MASHIMO H et al.: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature (1995) 377:196–197.
   PubMedGoogle Scholar
• STAMLER JS, LOH E, RODDY MA et al.: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation (1994) 89:2035–2040.
   PubMed Web of Science ®Google Scholar
• SIMON DI, STAMLER JS, LOH E et al.: Effect of nitric oxide synthase inhibition on bleeding time in humans. Cardiovasc. Pharmacol (1995) 26:339–342.
   PubMed Web of Science ®Google Scholar
• FREEDMAN JE, SAUTER R, BATTINELLI EM et al.: Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ. Res. (1999) 84:1421.
   Google Scholar
• KADER KN, AKELLA RN, ZIATS NP et al.: eN0S-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation M vitro Tissue Eng. (2000) 6:241-251.
   Google Scholar
• CARDILLO C, KILCOYNE CM, QUYYUMI AA et al.: Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation (1998) 97:851–856.
   PubMed Web of Science ®Google Scholar
• ZEIHER AM, DREXLER H, SAUBIER B,JUST H: Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. Clin. Invest. (1993) 92:652–662.
   Google Scholar
• SAENZ DE TEJADA I, GOLDSTEIN I, AZADZOI K et al.: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl. I Med. (1989) 320:1025–1030.
   Google Scholar
• MINOR RL Jr, MYERS PR, GUERRA R Jr et al.: Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest. (1990) 86:2109–2116.
   Google Scholar
• MEHTA JL, LOPEZ LM, CHEN L, COX OE: Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am. Cardiol (1994) 74:901–905.
   PubMed Web of Science ®Google Scholar
• OHARA Y, PETERSON TE, HARRISON DG: Hypercholesterolemia increases endothelial superoxide anion production. .1. Clin. Invest. (2003) 91:2546–2551.
   Google Scholar
• LANGENSTROER P, PIEPER GM: Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am. .1 Physiol (1992) 263:H257–H265.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN S, CZAPSKI G: The role ofthe reactions of 'NO with superoxide and oxygen in biological systems: a kinetic approach. Free Radic. Biol. Med. (1995) 19:785–794.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI K, YASUHIRO T, ASADA Y, SUGAWA Y: Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion (1998) 59:298–307.
   PubMed Web of Science ®Google Scholar
• LECHI C, ANDRIOLI G, GAINO S et al:The antiplatelet effects of a new nitroderivative of acetylsalicylic acid - an M vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thromb. Haemost. (1996) 76:791–798.
   PubMed Web of Science ®Google Scholar
• NAPOLI C, ACKAH E, DE NIGRIS F et al.: Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA (2002) 99:12467–12470.
   Google Scholar
• MOMI S, EMERSON M, PAUL W et al.: Prevention of pulmonary thromboembolism by NCX 4016, a nitricoxide-releasing aspirin. Ear: Pharmacol (2000) 397:177–185.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, MCKNIGHT W, DEL SOLDATO P et al.: Anti-thrombotic effects of a nitric oxide-releasing, gastric- sparing aspirin derivative. j Clin. Invest. (1995) 96:2711–2718.
   Google Scholar
• FIORUCCI S, SANTUCCI L, GRESELE P et al.: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology(2003) 124:600–607.
   PubMed Web of Science ®Google Scholar
• SAVAGE B, SIXMA JJ, RUGGERI ZM: Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc. Nati Acad. Sci. USA (2002) 99:425–430.
   PubMed Web of Science ®Google Scholar
• SAVAGE B, ALMUS-JACOBS F, RUGGERI ZM: Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell (1998) 94:657–666.
   PubMed Web of Science ®Google Scholar
• FUJIMURA Y, TITANI K, HOLLAND LZ et al.: von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein lb. J. Biol. Chem. (1986) 261:385.
   Google Scholar
• INBAL A, GUREVITZ 0, TAMARIN I et al.: Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: M vitro and ex vivo inhibition of platelet function. Blood (1999) 94:1693–1700.
   Google Scholar
• HYNES RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• WAGNER CL, MASCELLI MA, NEBLOCK DS et al.: Analysis of GPIIb/ IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:907–914.
   PubMed Web of Science ®Google Scholar
• CRAMER EM, SAVIDGE GE VAICHENKER W et al.: Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood (1990) 75:1220–1227.
   Google Scholar
• PEERSCHKE El: Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb. Haemost. (1995) 73:862–867.
   Web of Science ®Google Scholar
• FOX JE, REYNOLDS CC, AUSTIN CD:The role of calpain in stimulus-response coupling: evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets. Blood (1990) 76:2510–2519.
   PubMed Web of Science ®Google Scholar
• SIMS PJ, WIEDMER T, ESMON CT et al.: Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. Biol. Chem. (1989) 264:17049–17057.
   Google Scholar
• CAIRNS JA, THEROUX P, LEWIS HD Jr et al.: Antithrombotic agents in coronary artery disease. Chest (2001) 119:228S–252S.
   Google Scholar
• FRENETTE PS, JOHNSON RC, HYNES RO, WAGNER DD: Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. USA (1995) 92:7250–7254.
   Google Scholar
• MASSBERG S, ENDERS G, LEIDERER R et al.: Platelet-endothelial cell interactions during ischemia/ reperfusion: the role of P-selectin. Blood (1998) 92:507–515.
   PubMed Web of Science ®Google Scholar
• BERMAN CL, YEO EL, WENCEL-DRAKE JD et al.: A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J. Clic]. Invest. (1986) 78:130–137.
   Google Scholar
• LARSEN E, CELI A, GILBERT GE et al.: PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell (1989) 59:305–312.
   PubMed Web of Science ®Google Scholar
• MCEVER RP, CUMMINGS RD: Role ofPSGL-1 binding to selectins in leukocyte recruitment. Clin. Invest. (1997) 100:485–492.
   Google Scholar
• TAN KT, LIP GYH, BLANN AD: Post-stroke Inflammatory Response: Effects of Stroke Evolution and Outcome. Can: Atherosclec Rep. (2003) 5:245–251.
   PubMedGoogle Scholar
• HUO Y, SCHOBER A, FORLOW SB et al.: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. (2003) 9:61–67.
   PubMed Web of Science ®Google Scholar
• ••Excellent paper demonstrating a directpathophysiological role of platelets on atheromatous growth.
   Google Scholar
• PINSKY DJ, NAKA Y, LIAO H et al.: Hypcoda-induced exocytosis of endothelial cell weibel-palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation .j. Gin. Invest. (1996) 97:493–500.
   Google Scholar
• FURMAN MI, BARNARD MR, KRUEGER LA: Circulating monocyte- platelet aggregates are an early marker of acute myocardial infarction. Am. Coll. Cardiol. (1998) 31:352–358.
   PubMed Web of Science ®Google Scholar
• AULT KA, CANNON CP, MITCHELL J et al.: Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.' Am. Coll. Cardiol. (1999) 33:634–639.
   PubMed Web of Science ®Google Scholar
• KAMATH S, BLANN AD, CAINE GJ et al.: Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke (2002) 33:1237–1242.
   PubMed Web of Science ®Google Scholar
• DAVI G, ROMANO M, MEZZETTI A et al.: Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation (1998) 97:953–957.
   PubMed Web of Science ®Google Scholar
• KOYAMA H, MAENO T, FUKUMOTO S et al.: Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation (2003) 108:524–529.
   PubMed Web of Science ®Google Scholar
• CARON A, THEORET JF, MOUSA SA, MERHI Y: Anti-platelet effects of GPIIb/ Ma and P-selectin antagonism, platelet activation, and binding to neutrophils. Cardiovasc. Pharmacol. (2002) 40:296–306.
   PubMed Web of Science ®Google Scholar
• NEMOTO T, BURNE MJ, DANIELS F et al.: Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int. (2001) 60:2205–2214.
   PubMed Web of Science ®Google Scholar
• MOLENAAR TJ, APPELDOORN CC, DE HAAS SA et al.: Specific inhibition of P-selectin-mediated cell adhesion by phage display-derived peptide antagonists. Blood (2002) 100:3570–3577.
   Google Scholar
• ZOLDHELYI P, BECK PJ, BJERCKE RJ et al.: Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor. Am. Physiol. Heart Circ. Physiol. (2000) 279:H3065–H3075.
   PubMed Web of Science ®Google Scholar
• BLAKE GJ, RIDKER PM: C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. (2003) 41S:537–542.
   Google Scholar
• PRADHAN AD, RIFAI N, RIDKER PM: Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation (2002) 106:820–825.
   PubMed Web of Science ®Google Scholar
• BROWN DA, BREIT SN, BURING J et al.: Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet (2002) 359:2159–2163.
   PubMed Web of Science ®Google Scholar
• PHIPPS RP: Atherosclerosis: the emerging role of inflammation and the CD4O-CD40 ligand system. Proc. Nati Acad. Sci. USA (2000) 97:6930–6932.
   PubMed Web of Science ®Google Scholar
• •Good introduction to CD4OL.
   Google Scholar
• BLAKE GJ, RIDKER PM: Inflammatory bio-markers and cardiovascular risk prediction. Intern. Med. (2002) 252:283–294.
   Web of Science ®Google Scholar
• KAMEYOSHI Y, DORSCHNER A, MALLET Al et al.: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. Exp. Med. (1992) 176:587–592.
   PubMed Web of Science ®Google Scholar
• VON HUNDELSHAUSEN P, WEBER KS, HUO Y et al.: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 103:1772–1777.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AE, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271:2599–2603.
   PubMed Web of Science ®Google Scholar
• MACK M, PFIRSTINGERJ, WEBER C et al.: Chondroitin sulfate A released from platelets blocks RANTES presentation on cell surfaces and RANTES-dependent firm adhesion of leukocytes. Ear: j Immunol. (2002) 32:1012–1020.
   PubMed Web of Science ®Google Scholar
• HAWRYLOWICZ CM, HOWELLS GL, FELDMANN M: Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. I Exp. Med. (1991) 174:785–790.
   PubMed Web of Science ®Google Scholar
• LOPPNOW H, BIL R, HIRT S et al.: Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood (1998) 91:134–141.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHONBECK U, SUKHOVA GK et al.: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA (1997) 94:1931–1936.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHONBECK U, SUKHOVA GK et al.: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 394:200–203.
   PubMed Web of Science ®Google Scholar
• LUTGENS E, GORELIK L, DAEMEN MJ et al.: Requirement for CD154 in the progression of atherosclerosis. Nat. Med. (1999) 5:1313–1316.
   PubMed Web of Science ®Google Scholar
• BLAKE GJ, OSTFELD RJ, YUCEL EK et al.: Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscier. Thromb. Vase. Biol. (2003) 23:ell-e14.
   Google Scholar
• SCHONBECK U, MACH F, SUKHOVA GK et al.: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. (1997) 81:448–454.
   Google Scholar
• HEIJNEN HF, SCHIEL AE, FIJNHEER R et al.: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood (1999) 94:3791–3799.
   PubMed Web of Science ®Google Scholar
• DACHARY-PRIGENT J, FREYSSINET JM, PASQUET JM et al.: Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood (1993) 81:2554–2565.
   PubMed Web of Science ®Google Scholar
• CHOW TW, HELLUMS JD, THIAGARAJAN P: Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. Lab. Clin. Med. (2000) 135:66–72.
   PubMedGoogle Scholar
• WIEDMER T, SHATTIL SJ, CUNNINGHAM M, SIMS PJ: Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet Factor Va receptor. Biochemistry (1990) 29:623–632.
   PubMed Web of Science ®Google Scholar
• GILBERT GE, SIMS PJ, WIEDMER T et al.: Platelet-derived microparticles express high affinity receptors for Factor VIII. J. Biol. Chem. (1991) 266:17261–17268.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M, MONROE DM, ROBERTS HR: Coagulation Factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb. Haemost. (1992) 68:74–78.
   PubMed Web of Science ®Google Scholar
• NIEUWLAND R, BERCKMANS RJ, ROTTEVEEL-EIJKMAN et al: Cell- derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 96:3534–3541.
   PubMed Web of Science ®Google Scholar
• PRESTON RA, JY W, JIMENEZ JJ et al.: Effects of severe hypertension on endothelial and platelet microparticles. Hypertension (2003) 41:211–217.
   PubMed Web of Science ®Google Scholar
• JOOP K, BERCKMANS RJ, NIEUWLAND R et al.: Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb. Haemost. (2001) 85:820.
   Google Scholar
• SABATIER F, DARMON P, HUGEL B et al.: Type 1 and Type 2 diabetic patients display different patterns of cellular microparticles. Diabetes (2002) 51:2840–2845.
   PubMed Web of Science ®Google Scholar
• SINGH N, GEMMELL CH, DALY PA, YEO EL: Elevated platelet-derived microparticle levels during unstable angina. Can.j Cardiol. (1995) 11:1015–1021.
   PubMed Web of Science ®Google Scholar
• BARRY OP, PRATICO D, LAWSON JA, FITZGERALD GA: Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. Clin. Invest. (1997) 99:2118–2127.
   Google Scholar
• BARRY OP, PRATICO D, SAVANI RC, FITZGERALD GA: Modulation of monocyte-endothelial cell interactions by platelet microparticles. Clin. Invest. (1998) 102:136–144.
   Google Scholar